Cargando…

Oxidative Stress in Schizophrenia

Increasing evidence indicates that oxidative damage exists in schizophrenia. Available literature about possible mechanisms of oxidative stress induction was reviewed. Furthermore, possibilities of measuring biomarkers of schizophrenia outside the central nervous system compartment, their specificit...

Descripción completa

Detalles Bibliográficos
Autores principales: Bošković, Marija, Vovk, Tomaž, Kores Plesničar, Blanka, Grabnar, Iztok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers Ltd 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131721/
https://www.ncbi.nlm.nih.gov/pubmed/22131939
http://dx.doi.org/10.2174/157015911795596595
_version_ 1782207750515720192
author Bošković, Marija
Vovk, Tomaž
Kores Plesničar, Blanka
Grabnar, Iztok
author_facet Bošković, Marija
Vovk, Tomaž
Kores Plesničar, Blanka
Grabnar, Iztok
author_sort Bošković, Marija
collection PubMed
description Increasing evidence indicates that oxidative damage exists in schizophrenia. Available literature about possible mechanisms of oxidative stress induction was reviewed. Furthermore, possibilities of measuring biomarkers of schizophrenia outside the central nervous system compartment, their specificity for different types of schizophrenia and potential therapeutic strategies to prevent oxidative injuries in schizophrenia were discussed. Data were extracted from published literature found in Medline, Embase, Biosis, Cochrane and Web of Science, together with hand search of references. Search terms were: schizophrenia, oxidative stress, antipsychotics, antioxidants and fatty acids. Finding a sensitive, specific and non invasive biomarker of schizophrenia, which could be measured in peripheral tissue, still stays an important task. Antioxidant enzymes, markers of lipid peroxidation, oxidatively modified proteins and DNA are most commonly used. As it considers the supplemental therapy, according to our meta-analysis vitamin E could potentially improve tardive dyskinesia, while for the effect of therapy with polyunsaturated fatty acids there is no clear evidence. Oxidative stress is a part of the pathology in schizophrenia and appears as a promising field to develop new therapeutic strategies. There is a need for well designed, placebo controlled trials with supplementation therapy in schizophrenia.
format Online
Article
Text
id pubmed-3131721
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Bentham Science Publishers Ltd
record_format MEDLINE/PubMed
spelling pubmed-31317212011-12-01 Oxidative Stress in Schizophrenia Bošković, Marija Vovk, Tomaž Kores Plesničar, Blanka Grabnar, Iztok Curr Neuropharmacol Article Increasing evidence indicates that oxidative damage exists in schizophrenia. Available literature about possible mechanisms of oxidative stress induction was reviewed. Furthermore, possibilities of measuring biomarkers of schizophrenia outside the central nervous system compartment, their specificity for different types of schizophrenia and potential therapeutic strategies to prevent oxidative injuries in schizophrenia were discussed. Data were extracted from published literature found in Medline, Embase, Biosis, Cochrane and Web of Science, together with hand search of references. Search terms were: schizophrenia, oxidative stress, antipsychotics, antioxidants and fatty acids. Finding a sensitive, specific and non invasive biomarker of schizophrenia, which could be measured in peripheral tissue, still stays an important task. Antioxidant enzymes, markers of lipid peroxidation, oxidatively modified proteins and DNA are most commonly used. As it considers the supplemental therapy, according to our meta-analysis vitamin E could potentially improve tardive dyskinesia, while for the effect of therapy with polyunsaturated fatty acids there is no clear evidence. Oxidative stress is a part of the pathology in schizophrenia and appears as a promising field to develop new therapeutic strategies. There is a need for well designed, placebo controlled trials with supplementation therapy in schizophrenia. Bentham Science Publishers Ltd 2011-06 /pmc/articles/PMC3131721/ /pubmed/22131939 http://dx.doi.org/10.2174/157015911795596595 Text en ©2011 Bentham Science Publishers Ltd http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Bošković, Marija
Vovk, Tomaž
Kores Plesničar, Blanka
Grabnar, Iztok
Oxidative Stress in Schizophrenia
title Oxidative Stress in Schizophrenia
title_full Oxidative Stress in Schizophrenia
title_fullStr Oxidative Stress in Schizophrenia
title_full_unstemmed Oxidative Stress in Schizophrenia
title_short Oxidative Stress in Schizophrenia
title_sort oxidative stress in schizophrenia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131721/
https://www.ncbi.nlm.nih.gov/pubmed/22131939
http://dx.doi.org/10.2174/157015911795596595
work_keys_str_mv AT boskovicmarija oxidativestressinschizophrenia
AT vovktomaz oxidativestressinschizophrenia
AT koresplesnicarblanka oxidativestressinschizophrenia
AT grabnariztok oxidativestressinschizophrenia